Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CELC Celcuity
10.410-0.160-1.51%
Close
01/27 16:00 ET
10.4100.0000.00%
Post Mkt Price 01/27 16:41 ET
High
10.770
Open
10.080
Turnover
475.55K
Low
10.080
Pre Close
10.570
Volume
45.57K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
DMTK, RYAM and BIOR Among Mid-day Movers
RSLS, ATNF and CELC Among Mid-day Movers
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersBellerophon Therapeutics (NASDAQ:BLPH) stock rose 171.1% to $2.48 during Thursday's regular session. As of 12:30 EST, this security is trading at a volume of 51.2 million shares, making up 2745
Celcuity Inc. (NASDAQ:CELC) Insiders Have a Reason to Boast After Seeing a US$2.0m Addition to Their US$1.6m Investment
Last week, Celcuity Inc. (NASDAQ:CELC) insiders, who had purchased shares in the previous 12 months were rewarded handsomely. The shares increased by 33% last week, resulting in a US$51m increase in t
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Celcuity Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.Axcella Heal
TELL, ICPT and VKTX Among Mid-day Movers
Bullish Insiders Bet US$1.6m on Celcuity Inc. (NASDAQ:CELC)
Celcuity CEO Brian F. Sullivan Reported Purchase of 636,512 Shares @ Avg Price of $2.36/Share in Form 4 Filing on Tuesday
Celcuity CEO Brian F. Sullivan Reported Purchase of 636,512 Shares @ Avg Price of $2.36/Share in Form 4 Filing on Tuesday
Fly Intel: After-Hours Movers
Company Overview
More
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
CEO： Mr. Brian F. Sullivan
Market： NASDAQ
Listing Date： 09/20/2017
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet